News

Goldfinch Bio has raised $100 Million to support the advancement of its TRPC5 inhibitor and cannabinoid receptor 1 inverse agonist for the treatment of kidney diseases

BY      |     June 30, 2020

Goldfinch Bio, a clinical stage biotechnology company developing novel medicines for the treatment of kidney diseases, announced that it has raised $100 Million to advance its TRPC5 inhibitor (GFB-887) and cannabinoid receptor 1 inverse agonist (GFB-024) for the treatment of kidney diseases.

The Company plans to initiate a Phase 2 clinical trial of GFB-887 in patients with focal segmental glomerulosclerosis and diabetic nephropathy, two diseases often driven by overactivation of the TRPC5-Rac1 pathway, in 2020-2021.

Read the press release here.

Read more about Goldfinch Bio here.



Photo by Robina Weermeijer on Unsplash


Comments? Questions? Suggestions?

If you have any comments, questions or suggestions concerning this article, feel free to email me at [email protected]
Alternatively, you can leave your comments on LinkedIn or Twitter.